Skip to main content
Top
Published in: Clinical Rheumatology 3/2014

01-03-2014 | Original Article

Relationship between serum leptin level and disease activity in patients with systemic sclerosis

Authors: Mahmut Budulgan, Banu Dilek, Şevin Buluttekin Dağ, İbrahim Batmaz, İsmail Yıldız, Mustafa Akif Sarıyıldız, Remzi Çevik, Kemal Nas

Published in: Clinical Rheumatology | Issue 3/2014

Login to get access

Abstract

To determine the relationship between serum leptin levels and disease activity in systemic sclerosis (SSc). A total of 60 subjects (30 controls and 30 patients) were included. The inflammatory markers and leptin levels were evaluated and body mass index (BMI) was measured for both groups. The assessment of the skin involvement was performed based on the modified Rodnan skin score (mRSS). Disease activity was evaluated according to the Valentini scleroderma disease activity index. There was a significant difference between the patient and control groups in terms of BMI (p < 0.05); however there was no difference with regards to age and gender (p > 0.05). Valentini scores and mRSS were determined to be significantly higher in active patients (n = 14) than in inactive patients (n = 16) (p < 0.05). No significant difference was determined between groups in terms of leptin levels (p > 0.05). However, leptin levels were significantly lower in active patients than in inactive patients (p < 0.05). We found a significant positive correlation between serum leptin and BMI (p < 0.05), and leptin and serum C3 levels (p < 0.05); no relationship was detected between leptin and other parameters. Leptin can be used as an activity marker in SSc. Further studies, including larger series, should be carried out to clarify this relationship.
Literature
1.
go back to reference Gilliland BC (2001) Systemic sclerosis (scleroderma). In: Braunwald E, Fauci AS, Kasper DL, Hauser SL, Longo DL, Jameson JL (eds) Harrison’s principles of internal medicine, 15th edn. McGraw-Hil, New York, pp 1937–1945 Gilliland BC (2001) Systemic sclerosis (scleroderma). In: Braunwald E, Fauci AS, Kasper DL, Hauser SL, Longo DL, Jameson JL (eds) Harrison’s principles of internal medicine, 15th edn. McGraw-Hil, New York, pp 1937–1945
2.
go back to reference Valentini G, Della Rossa A, Bombardieri S (2001) European multicentre study to define disease activity criteria for systemic sclerosis. II. Identification of disease activity variables and development of preliminary activity indices. Ann Rheum 60:592–598CrossRef Valentini G, Della Rossa A, Bombardieri S (2001) European multicentre study to define disease activity criteria for systemic sclerosis. II. Identification of disease activity variables and development of preliminary activity indices. Ann Rheum 60:592–598CrossRef
3.
go back to reference Clements P, Lachenbruch P, Seibold J, Wigley FM (1995) Inter- and intraobserver variability of total skin thickness score (modified Rodnan) in systemic sclerosis (SSc). J Rheum 22:1281–1285PubMed Clements P, Lachenbruch P, Seibold J, Wigley FM (1995) Inter- and intraobserver variability of total skin thickness score (modified Rodnan) in systemic sclerosis (SSc). J Rheum 22:1281–1285PubMed
4.
go back to reference Medsger TA Jr, Silman AJ, Steen VD, Black CM, Akesson A, Bacon PA et al (1999) A disease severity scale for systemic sclerosis: development and testing. J Rheum 26:2159–2167PubMed Medsger TA Jr, Silman AJ, Steen VD, Black CM, Akesson A, Bacon PA et al (1999) A disease severity scale for systemic sclerosis: development and testing. J Rheum 26:2159–2167PubMed
5.
go back to reference Mantzoros CS, Flier JS (2000) Editorial: leptin as a therapeutic agent—trials and tribulations. J Clin Endocrinol Metab 85(11):4000–4002PubMed Mantzoros CS, Flier JS (2000) Editorial: leptin as a therapeutic agent—trials and tribulations. J Clin Endocrinol Metab 85(11):4000–4002PubMed
6.
go back to reference Aslan K, Serdar Z, Tokullugil AH (2004) Multifonksiyonel hormon: leptin. Uludag Üniversitesi tıp fakültesi Dergisi 30:113–118 Aslan K, Serdar Z, Tokullugil AH (2004) Multifonksiyonel hormon: leptin. Uludag Üniversitesi tıp fakültesi Dergisi 30:113–118
7.
go back to reference Prions KB, O’Rahilly S (1997) Regulation of adipose cell number in man. Clin Sci 92:311 Prions KB, O’Rahilly S (1997) Regulation of adipose cell number in man. Clin Sci 92:311
8.
go back to reference Satoh N, Ogawa Y, Katsuura G et al (1997) Pathophysiological significance of the obese gene product, leptin, in ventromedial hypothalamus (VMH)-lesioned rats: evidence for loss of its satiety effect in VMH-lesioned rats. Endocrinology 138(3):947–954PubMed Satoh N, Ogawa Y, Katsuura G et al (1997) Pathophysiological significance of the obese gene product, leptin, in ventromedial hypothalamus (VMH)-lesioned rats: evidence for loss of its satiety effect in VMH-lesioned rats. Endocrinology 138(3):947–954PubMed
9.
go back to reference Clement K (1999) Leptin and the genetics of obesity. Acta Pediatr Suppl 88:51–57CrossRef Clement K (1999) Leptin and the genetics of obesity. Acta Pediatr Suppl 88:51–57CrossRef
10.
go back to reference Fantuzzi G, Faggioni R (2000) Leptin in the regulation of immunity, inflammation, and hematopoiesis. J Leukoc Biol 68:437–446PubMed Fantuzzi G, Faggioni R (2000) Leptin in the regulation of immunity, inflammation, and hematopoiesis. J Leukoc Biol 68:437–446PubMed
11.
go back to reference Anders HJ, Rihl M, Heufelder A, Loch O, Schattenkirchner M (1999) Leptin serum levels are not correlated with disease activity in patients with rheumatoid arthritis. Metabolism 48(6):745–748PubMedCrossRef Anders HJ, Rihl M, Heufelder A, Loch O, Schattenkirchner M (1999) Leptin serum levels are not correlated with disease activity in patients with rheumatoid arthritis. Metabolism 48(6):745–748PubMedCrossRef
12.
go back to reference Popa C, Netea MG, Radstake TR, Van der Meer JW, Stalenhoef AF, van Riel PL et al (2005) Markers of inflammation are negatively correlated with serum leptin in rheumatoid arthritis. Ann Rheum Dis 64(8):1195–1198PubMedCentralPubMedCrossRef Popa C, Netea MG, Radstake TR, Van der Meer JW, Stalenhoef AF, van Riel PL et al (2005) Markers of inflammation are negatively correlated with serum leptin in rheumatoid arthritis. Ann Rheum Dis 64(8):1195–1198PubMedCentralPubMedCrossRef
13.
go back to reference Gunaydin R, Kaya T, Atay A, Olmez N, Hur A, Koseoglu M (2006) Serum leptin levelsvin rheumatoid arthritis and relationship with disease activity. South Med J 99(10):1078–1083PubMedCrossRef Gunaydin R, Kaya T, Atay A, Olmez N, Hur A, Koseoglu M (2006) Serum leptin levelsvin rheumatoid arthritis and relationship with disease activity. South Med J 99(10):1078–1083PubMedCrossRef
14.
go back to reference Bokarewa M, Bokarew D, Hultgren O, Tarkowski A (2003) Leptin consumption in the inflamed joints of patients with rheumatoid arthritis. Ann Rheum Dis 62(10):952–956PubMedCentralPubMedCrossRef Bokarewa M, Bokarew D, Hultgren O, Tarkowski A (2003) Leptin consumption in the inflamed joints of patients with rheumatoid arthritis. Ann Rheum Dis 62(10):952–956PubMedCentralPubMedCrossRef
15.
go back to reference Toussirot E, Streit G, Nguyen NU, Dumoulin G, Le Huédé G, Saas P et al (2007) Adipose tissue, serum adipokines, and ghrelin in patients with ankylosing spondylitis. Metabolism 56(10):1383–1389PubMedCrossRef Toussirot E, Streit G, Nguyen NU, Dumoulin G, Le Huédé G, Saas P et al (2007) Adipose tissue, serum adipokines, and ghrelin in patients with ankylosing spondylitis. Metabolism 56(10):1383–1389PubMedCrossRef
16.
go back to reference Sari I, Demir T, Kozaci LD, Akar S, Kavak T, Birlik M et al (2007) Body composition, insulin, and leptin levels in patients with ankylosing spondylitis. Clin Rheumatol 26(9):1427–1432PubMedCrossRef Sari I, Demir T, Kozaci LD, Akar S, Kavak T, Birlik M et al (2007) Body composition, insulin, and leptin levels in patients with ankylosing spondylitis. Clin Rheumatol 26(9):1427–1432PubMedCrossRef
17.
go back to reference Park MC, Lee SW, Choi ST, Park YB, Lee SK (2007) Serum leptin levels correlate with interleukin-6 levels and disease activity in patients with ankylosing spondylitis. Scand J Rheumatol 36(2):101–106PubMedCrossRef Park MC, Lee SW, Choi ST, Park YB, Lee SK (2007) Serum leptin levels correlate with interleukin-6 levels and disease activity in patients with ankylosing spondylitis. Scand J Rheumatol 36(2):101–106PubMedCrossRef
18.
go back to reference Kavuncu S, Koç F, Kurt M, Eryüksel B, Ortaç S, Ozdal P, Firat E (2005) Evaluation of serum leptin concentration in Behçet’s disease with ocular involvement. Graefes Arch Clin Exp Ophthalmol 243(11):1158–1160PubMedCrossRef Kavuncu S, Koç F, Kurt M, Eryüksel B, Ortaç S, Ozdal P, Firat E (2005) Evaluation of serum leptin concentration in Behçet’s disease with ocular involvement. Graefes Arch Clin Exp Ophthalmol 243(11):1158–1160PubMedCrossRef
19.
go back to reference Evereklioglu C, Inalöz HS, Kirtak N, Doganay S, Bülbül M, Ozerol E, Er H, Ozbek E (2002) Serum leptin concentration is increased in patients with Behçet’s syndrome and is correlated with disease activity. Br J Dermatol 147(2):331–336PubMedCrossRef Evereklioglu C, Inalöz HS, Kirtak N, Doganay S, Bülbül M, Ozerol E, Er H, Ozbek E (2002) Serum leptin concentration is increased in patients with Behçet’s syndrome and is correlated with disease activity. Br J Dermatol 147(2):331–336PubMedCrossRef
20.
go back to reference Wisłowska M, Rok M, Stepień K, Kuklo-Kowalska A (2008) Serum leptin in systemic lupus erythematosus. Rheumatol Int 28(5):467–473PubMedCrossRef Wisłowska M, Rok M, Stepień K, Kuklo-Kowalska A (2008) Serum leptin in systemic lupus erythematosus. Rheumatol Int 28(5):467–473PubMedCrossRef
21.
go back to reference Kotulska A, Kucharz EJ, Brzezińska-Wcisło L, Wadas U (2001) A decreased serum leptin level in patients with systemic sclerosis. Clin Rheumatol 20(4):300–302PubMedCrossRef Kotulska A, Kucharz EJ, Brzezińska-Wcisło L, Wadas U (2001) A decreased serum leptin level in patients with systemic sclerosis. Clin Rheumatol 20(4):300–302PubMedCrossRef
22.
go back to reference Riccieri V, Stefanantoni K, Vasile M, Macrì V, Sciarra I, Iannace N, Alessandri C, Valesini G (2011) Abnormal plasma levels of different angiogenic molecules are associated with different clinical manifestations in patients with systemic sclerosis. Clin Exp Rheumatol 29(2 Suppl 65):S46–S52PubMed Riccieri V, Stefanantoni K, Vasile M, Macrì V, Sciarra I, Iannace N, Alessandri C, Valesini G (2011) Abnormal plasma levels of different angiogenic molecules are associated with different clinical manifestations in patients with systemic sclerosis. Clin Exp Rheumatol 29(2 Suppl 65):S46–S52PubMed
23.
go back to reference Pehlivan Y, Onat AM, Ceylan N, Turkbeyler IH, Buyukhatipoglu H, Comez G, Babacan T, Tarakcioglu M (2012) Serum leptin, resistin and TNF-α levels in patients with systemic sclerosis: the role of adipokines in scleroderma. Int J Rheum Dis 15(4):374–379PubMedCrossRef Pehlivan Y, Onat AM, Ceylan N, Turkbeyler IH, Buyukhatipoglu H, Comez G, Babacan T, Tarakcioglu M (2012) Serum leptin, resistin and TNF-α levels in patients with systemic sclerosis: the role of adipokines in scleroderma. Int J Rheum Dis 15(4):374–379PubMedCrossRef
24.
go back to reference Masi AT, Rodnan GP, Medsger TA Jr et al (1980) Subcommittee for Scleroderma Criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee: preliminary criteria for the classification of systemic sclerosis (scleroderma). Arthritis Rheum 23:581–590CrossRef Masi AT, Rodnan GP, Medsger TA Jr et al (1980) Subcommittee for Scleroderma Criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee: preliminary criteria for the classification of systemic sclerosis (scleroderma). Arthritis Rheum 23:581–590CrossRef
25.
go back to reference Clements P, Lachenbruch P, Siebold J et al (1995) Inter and intraobserver variability of total skin thickness score (modified Rodnan TSS) in systemic sclerosis. J Rheumatol 22(7):1281–1285PubMed Clements P, Lachenbruch P, Siebold J et al (1995) Inter and intraobserver variability of total skin thickness score (modified Rodnan TSS) in systemic sclerosis. J Rheumatol 22(7):1281–1285PubMed
26.
go back to reference Valentini G, D’Angelo S, Della Rossa A, Bencivelli W, Bombardieri S (2003) European Scleroderma Study Group to define disease activity criteria for systemic sclerosis. IV. Assessment of skin thickening by modified Rodnan skin score. Ann Rheum Dis 62(9):904–905PubMedCentralPubMedCrossRef Valentini G, D’Angelo S, Della Rossa A, Bencivelli W, Bombardieri S (2003) European Scleroderma Study Group to define disease activity criteria for systemic sclerosis. IV. Assessment of skin thickening by modified Rodnan skin score. Ann Rheum Dis 62(9):904–905PubMedCentralPubMedCrossRef
27.
28.
go back to reference La Cava A, Alviggi C, Matarese G (2004) Unraveling the multiple roles of leptin in inflammation and autoimmunity. J Mol Med 82:4–11PubMedCrossRef La Cava A, Alviggi C, Matarese G (2004) Unraveling the multiple roles of leptin in inflammation and autoimmunity. J Mol Med 82:4–11PubMedCrossRef
29.
go back to reference Shamsuzzaman AS, Winnicki M, Wolk R et al (2004) Independent association between plasma leptin and C-reactive protein in healthy humans. Circulation 109:2181–2185PubMedCrossRef Shamsuzzaman AS, Winnicki M, Wolk R et al (2004) Independent association between plasma leptin and C-reactive protein in healthy humans. Circulation 109:2181–2185PubMedCrossRef
30.
go back to reference Dagogo JS, Fanelli C, Paramore D et al (1996) Plasma leptin and insulin relationships in obese and nonobese humans (abstract). Diabetes 45:695–698CrossRef Dagogo JS, Fanelli C, Paramore D et al (1996) Plasma leptin and insulin relationships in obese and nonobese humans (abstract). Diabetes 45:695–698CrossRef
Metadata
Title
Relationship between serum leptin level and disease activity in patients with systemic sclerosis
Authors
Mahmut Budulgan
Banu Dilek
Şevin Buluttekin Dağ
İbrahim Batmaz
İsmail Yıldız
Mustafa Akif Sarıyıldız
Remzi Çevik
Kemal Nas
Publication date
01-03-2014
Publisher
Springer London
Published in
Clinical Rheumatology / Issue 3/2014
Print ISSN: 0770-3198
Electronic ISSN: 1434-9949
DOI
https://doi.org/10.1007/s10067-013-2459-0

Other articles of this Issue 3/2014

Clinical Rheumatology 3/2014 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.